| Publication |
Sentence |
Publish Date |
Extraction Date |
Species |
| Dan Alexandru Niculescu, Monica Livia Gheorghiu, Catalina Poian. Radiotherapy in aggressive or dopamine agonists resistant prolactinomas; is it still worthwhile? European journal of endocrinology. 2023-03-28. PMID:36975104. |
however, considering the radiotherapy side effects, notably hypopituitarism, as opposed to the high efficacy and low toxicity of dopamine agonists (da) treatment and neurosurgery, radiotherapy is recommended mostly for patients with aggressive or high-risk prolactinomas or in those resistant or intolerant to medical therapy, usually after surgical failure. |
2023-03-28 |
2023-08-14 |
Not clear |
| Maria Markou, Aikaterini Lavrentaki, Georgia Ntal. Recent advances in understanding and managing pituitary adenomas. Faculty reviews. vol 12. 2023-03-27. PMID:36968144. |
dopamine agonists (das) are traditionally the first-line treatment for prolactinomas. |
2023-03-27 |
2023-08-14 |
Not clear |
| Tuqa Bazuhair, Bakhitah Aleid, Mussa Almalk. Effect of Tamoxifen on the Management of Dopamine Agonist-Resistant Prolactinomas: A Systematic Review. Cureus. vol 15. issue 2. 2023-03-23. PMID:36950000. |
effect of tamoxifen on the management of dopamine agonist-resistant prolactinomas: a systematic review. |
2023-03-23 |
2023-08-14 |
Not clear |
| Tuqa Bazuhair, Bakhitah Aleid, Mussa Almalk. Effect of Tamoxifen on the Management of Dopamine Agonist-Resistant Prolactinomas: A Systematic Review. Cureus. vol 15. issue 2. 2023-03-23. PMID:36950000. |
the management of dopamine agonist (da)-resistant prolactinomas unresponsive to second and third-line treatment is challenging and requires alternative medical therapy. |
2023-03-23 |
2023-08-14 |
Not clear |
| Stephan Petersen. [Management of prolactinoma prior to, during, and after pregnancy]. Deutsche medizinische Wochenschrift (1946). vol 148. issue 7. 2023-03-20. PMID:36940687. |
underlying prolactinomas may successfully be treated with dopamine agonists. |
2023-03-20 |
2023-08-14 |
Not clear |
| Eng-Loon Tng, Ada Ee Der Teo, Aye Thida Aun. Macroprolactinoma with secondary resistance to dopamine agonists: a case report and review of the literature. Journal of medical case reports. vol 17. issue 1. 2023-03-17. PMID:36927797. |
resistance to dopamine agonists is not uncommonly seen in prolactinomas. |
2023-03-17 |
2023-08-14 |
Not clear |
| Charles Springer, Robert Rodgers, Gina Vivino, Saritha Attanagoda, Charles Dylan Mik. A Case Report of Delusions in a Patient Receiving Cabergoline Therapy for Prolactinoma: Pathophysiology and Proposed Treatment With Aripiprazole. Clinical neuropharmacology. 2023-03-06. PMID:36877861. |
cabergoline is a dopamine 2 receptor agonist used as first-line treatment of pituitary prolactinomas. |
2023-03-06 |
2023-08-14 |
Not clear |
| N Wu, D Zhu, J Li, X Li, Z Zhu, Q Rao, B Hu, H Wang, Y Zh. CircOMA1 modulates cabergoline resistance by downregulating ferroptosis in prolactinoma. Journal of endocrinological investigation. 2023-02-28. PMID:36853491. |
dopamine agonists are the main treatment for prolactinoma, but a small number of patients are still resistant to pharmacotherapy. |
2023-02-28 |
2023-08-14 |
Not clear |
| Amit Akirov, Yaron Rudma. The Role of Aromatase Inhibitors in Male Prolactinoma. Journal of clinical medicine. vol 12. issue 4. 2023-02-25. PMID:36835974. |
dopamine agonists are the recommended treatment for male prolactinomas, but some patients may develop dopamine-agonist-resistant hyperprolactinemia, leading to persistent hypogonadism that requires treatment with testosterone. |
2023-02-25 |
2023-08-14 |
Not clear |
| Jimena Ferrari. Is prolactin receptor signaling a target in dopamine-resistant prolactinomas? Frontiers in endocrinology. vol 13. 2023-01-30. PMID:36714572. |
the treatment of prl-secreting tumors, formerly known as prolactinomas, has relied mainly on this physiological characteristic, making dopamine agonists the first therapeutic alternative. |
2023-01-30 |
2023-08-14 |
Not clear |
| Andrea Glezer, Mariana Ramos Santana, Marcello D Bronstein, Jose Donato, Raquel Soares Jalla. The interplay between prolactin and cardiovascular disease. Frontiers in endocrinology. vol 13. 2023-01-27. PMID:36704037. |
a recent study showed a decrease in total and ldl- cholesterol only in men with prolactinoma treated with dopamine agonists (da) supporting the previous results of a population study with increased cvd risk in men harboring prolactinoma. |
2023-01-27 |
2023-08-14 |
Not clear |
| Hao Tang, Yijun Cheng, Xiaohui Lou, Hong Yao, Jing Xie, Weiting Gu, Xinyun Huang, Yanting Liu, Shaojian Lin, Yuting Dai, Li Xue, Xiaozhu Lin, Zhe Bao W. DRD2 expression based on Endocrine. 2023-01-23. PMID:36689171. |
drd2 expression based on the dopamine agonists (da) have been used widely to treat prolactinomas. |
2023-01-23 |
2023-08-14 |
Not clear |
| Andrea Ramos de Castro Moreira, Ericka Trarbach, Cristina Bellotti Formiga Bueno, Anna Louise Stellfeld Monteiro, Isabella Pacetti Pajaro Grande, Mario Padula, Gustavo Arantes Rosa Maciel, Andrea Gleze. PRL-R variants are not only associated with prolactinomas but also with dopamine agonist resistance. The Journal of clinical endocrinology and metabolism. 2023-01-13. PMID:36638053. |
prl-r variants are not only associated with prolactinomas but also with dopamine agonist resistance. |
2023-01-13 |
2023-08-14 |
mouse |
| Tamara L Wexler, Gabrielle Page-Wilso. Dopamine Agonists for the Treatment of Pituitary Tumors: From Ergot Extracts to Next Generation Therapies. British journal of clinical pharmacology. 2023-01-11. PMID:36630197. |
here we review the development and role of dopamine agonist for the treatment of prolactinomas, the literature supporting their adjuvant use for the treatment of all other pituitary tumors, and recent progress in the development of the next generation of chimeric compounds that target d2, and other receptor subtypes highly expressed on pituitary tumor cells. |
2023-01-11 |
2023-08-14 |
Not clear |
| Sardar Ali Khan, Waqas Shafiq, Umal Azmat, Ahmed Imran Siddiqi, Asim Munir Alvi, Sara Ashfaq, Hira Irfan, Muhammad Abu Bakar, Kashif Asgha. Radiation therapy outcomes of patients with pituitary macroadenoma. Biomedical reports. vol 18. issue 2. 2022-12-26. PMID:36568037. |
pituitary adenomas are one of the most common benign intracranial tumors, which are normally treated with surgery along with radiation therapy and medication such as dopamine agonist in prolactinoma. |
2022-12-26 |
2023-08-14 |
Not clear |
| Andrei Adrian Tica, Daniela Dumitrescu, Irina Tica, Corina Neamţu, Vlad Iustin Tica, Cristiana Iulia Dumitrescu, Oana Sorina Tic. Cabergoline Failure and a Spontaneous Pregnancy in a Microprolactinoma with High Prolactin Levels. Journal of personalized medicine. vol 12. issue 12. 2022-12-23. PMID:36556282. |
we report a particular case of a spontaneously occurring pregnancy in a long-term amenorrheic patient due to a prolactinoma with high serum prolactin (prl) following the failure of dopamine agonist therapy (da) for infertility. |
2022-12-23 |
2023-08-14 |
Not clear |
| Serdar Sahin, Tugce Sudutan, Yasin Kavla, Emre Durcan, Yeliz Yagiz Özogul, Burc Cagri Poyraz, Muge Sayitoglu, Hande Mefkure Ozkaya, Pinar Kadiogl. A Genetic Assessment of Dopamine Agonist-Induced Impulse Control Disorder in Patients with Prolactinoma. The Journal of clinical endocrinology and metabolism. 2022-12-09. PMID:36494095. |
a genetic assessment of dopamine agonist-induced impulse control disorder in patients with prolactinoma. |
2022-12-09 |
2023-08-14 |
Not clear |
| Serdar Sahin, Tugce Sudutan, Yasin Kavla, Emre Durcan, Yeliz Yagiz Özogul, Burc Cagri Poyraz, Muge Sayitoglu, Hande Mefkure Ozkaya, Pinar Kadiogl. A Genetic Assessment of Dopamine Agonist-Induced Impulse Control Disorder in Patients with Prolactinoma. The Journal of clinical endocrinology and metabolism. 2022-12-09. PMID:36494095. |
dopamine agonist-induced (da-induced) impulse control disorder (icd) represents a group of behavioral disorders that are increasingly recognized in patients with prolactinoma. |
2022-12-09 |
2023-08-14 |
Not clear |
| Hira Irfan, Waqas Shafiq, Ahmed Imran Siddiqi, Sara Ashfaq, Sadaf Attaullah, Asim Munir Alvi, Sardar Ali Khan, Muhammad Abu Bakar, Umal Azma. Prolactinoma: Clinical Characteristics, Management and Outcome. Cureus. vol 14. issue 10. 2022-11-07. PMID:36337795. |
aim prolactinoma, a prolactin (prl) secreting functioning pituitary tumor, is the most common of all pituitary adenomas (pa) accounting for 40-60% and dopamine agonists (da) are the cornerstone of treatment. |
2022-11-07 |
2023-08-14 |
Not clear |
| Hira Irfan, Waqas Shafiq, Ahmed Imran Siddiqi, Sara Ashfaq, Sadaf Attaullah, Asim Munir Alvi, Sardar Ali Khan, Muhammad Abu Bakar, Umal Azma. Prolactinoma: Clinical Characteristics, Management and Outcome. Cureus. vol 14. issue 10. 2022-11-07. PMID:36337795. |
medical records were used to retrieve for patient's demographics, clinical features at diagnosis, prl levels and size of prolactinoma on mri at diagnosis and after start of dopamine agonists and outcome of medical management. |
2022-11-07 |
2023-08-14 |
Not clear |